IN2015KN00007A - - Google Patents

Info

Publication number
IN2015KN00007A
IN2015KN00007A IN7KON2015A IN2015KN00007A IN 2015KN00007 A IN2015KN00007 A IN 2015KN00007A IN 7KON2015 A IN7KON2015 A IN 7KON2015A IN 2015KN00007 A IN2015KN00007 A IN 2015KN00007A
Authority
IN
India
Prior art keywords
tau
antibodies
methods
relates
Prior art date
Application number
Other languages
English (en)
Inventor
David Holtzman
Hong Jiang
Marc Diamond
Najla Kfoury
Brandon Holmes
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of IN2015KN00007A publication Critical patent/IN2015KN00007A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
IN7KON2015 2012-07-03 2013-07-03 IN2015KN00007A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261667515P 2012-07-03 2012-07-03
US201261694989P 2012-08-30 2012-08-30
PCT/US2013/049333 WO2014008404A1 (fr) 2012-07-03 2013-07-03 Anticorps dirigés contre tau

Publications (1)

Publication Number Publication Date
IN2015KN00007A true IN2015KN00007A (fr) 2015-07-31

Family

ID=49882495

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7KON2015 IN2015KN00007A (fr) 2012-07-03 2013-07-03

Country Status (16)

Country Link
US (2) US9834596B2 (fr)
EP (2) EP2870176A4 (fr)
JP (3) JP6345655B2 (fr)
KR (3) KR20200013072A (fr)
CN (2) CN104781278B (fr)
AU (3) AU2013286680B2 (fr)
CA (1) CA2877397A1 (fr)
HK (1) HK1209768A1 (fr)
IL (3) IL236409B (fr)
IN (1) IN2015KN00007A (fr)
MX (2) MX359555B (fr)
MY (1) MY171473A (fr)
NZ (2) NZ703423A (fr)
RU (2) RU2668159C2 (fr)
SG (3) SG10201708959WA (fr)
WO (1) WO2014008404A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104781278B (zh) 2012-07-03 2018-06-12 华盛顿大学 针对tau的抗体
MX359817B (es) 2012-08-16 2018-10-11 Ipierian Inc Anticuerpos que se enlazan a tau.
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
AU2014248515B2 (en) * 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
WO2015165961A1 (fr) 2014-04-29 2015-11-05 Affiris Ag Traitement et prévention de la maladie d'alzheimer
CN107074935B (zh) * 2014-06-26 2021-08-03 扬森疫苗与预防公司 特异性结合微管相关蛋白tau的抗体和抗原结合片段
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TWI664190B (zh) * 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
KR102502356B1 (ko) 2014-09-30 2023-02-21 워싱턴 유니버시티 타우 (tau) 활동 계측
MA41451A (fr) * 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
AR103713A1 (es) 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
CN107849124B (zh) 2015-06-05 2021-09-24 基因泰克公司 抗tau抗体及使用方法
US10287343B2 (en) * 2015-07-06 2019-05-14 Ucb Biopharma Sprl Tau-binding antibodies
MA41669A1 (fr) 2015-07-06 2018-05-31 Ucb Biopharma Sprl Anticorps se liant a tau
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
PT3334761T (pt) * 2015-08-13 2023-08-17 Univ New York Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias
CN105158483A (zh) * 2015-09-16 2015-12-16 北京九强生物技术股份有限公司 一种人肌钙蛋白i的超敏定量测定试剂盒及其检测方法
CN109415434B (zh) 2016-05-02 2022-12-30 普罗塞纳生物科学有限公司 识别tau的抗体
KR102471787B1 (ko) 2016-05-02 2022-11-29 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
MY197836A (en) 2016-07-12 2023-07-20 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
WO2018031361A2 (fr) 2016-08-09 2018-02-15 Eli Lilly And Company Polythérapie
KR102593669B1 (ko) 2016-11-15 2023-10-25 하. 룬드벡 아크티에셀스카브 시누클레인병증의 치료를 위한 제제, 용도 및 방법
AU2017373884A1 (en) 2016-12-07 2019-05-30 Ac Immune Sa Anti-tau antibodies and methods of their use
CR20230163A (es) 2016-12-07 2023-07-06 Genentech Inc ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271)
CN106749658B (zh) * 2016-12-15 2019-11-12 北京师范大学 抑制Tau蛋白聚集的抗体型分子伴侣
MA47019A (fr) 2016-12-16 2021-04-21 H Lundbeck As Agents, utilisations et procédés
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3583123A1 (fr) * 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anticorps anti-tau et leurs procédés d'utilisation
EP3592387A4 (fr) * 2017-03-09 2021-03-31 The Board of Trustees of the Leland Stanford Junior University Traitement de tumeurs cérébrales pédiatriques avec ciblage de la voie cd47
CA3061516A1 (fr) 2017-05-02 2018-11-08 Prothena Biosciences Limited Anticorps reconnaissant la proteine tau
TWI750419B (zh) * 2017-10-16 2021-12-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
CA3094934A1 (fr) 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Formulations aqueuses stables d'anticorps anti-tau
US11629175B2 (en) 2018-04-27 2023-04-18 Ecole Polytechnique Federale De Lausanne (Epfl) Method for preparing PHFS-like Tau aggregates
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
CN109613242A (zh) * 2018-11-01 2019-04-12 深圳天辰医疗科技有限公司 一种肌酸激酶同工酶检测试剂盒及其制备方法
WO2020180819A1 (fr) 2019-03-03 2020-09-10 Prothena Biosciences Limited Anticorps reconnaissant la protéine tau
EP3769090B1 (fr) 2019-03-18 2023-11-15 Regeneron Pharmaceuticals, Inc. Plate-forme de criblage crispr/cas pour révéler des vulnérabilités génétiques associées à une agrégation de tau
KR20210141522A (ko) 2019-03-18 2021-11-23 리제너론 파마슈티칼스 인코포레이티드 타우 시딩 또는 응집의 유전적 변형제를 식별하기 위한 CRISPR/Cas 스크리닝 플랫폼
CN110055280A (zh) * 2019-03-19 2019-07-26 深圳大学 一种稳定表达mCherry-tau的细胞系及其构建方法与应用
GB2600599A (en) * 2019-07-15 2022-05-04 Adel Inc Anti-tau antibody and use of same
CA3156678A1 (fr) 2019-10-09 2021-04-15 Bluerock Therapeutics Lp Cellules a expression transgenique soutenue
EP4069734A1 (fr) * 2019-12-04 2022-10-12 AC Immune SA Nouvelles molécules de thérapie et de diagnostic
EP4241088A1 (fr) * 2020-11-09 2023-09-13 Meso Scale Technologies, LLC Procédés et kits pour détecter la protéine tau
WO2022144406A1 (fr) 2020-12-29 2022-07-07 Neurimmune Ag Anticorps anti-tau humains
IL307170A (en) 2021-03-26 2023-11-01 Janssen Biotech Inc Anti-tau antibodies and their uses
AU2022246275A1 (en) 2021-03-26 2023-11-09 Janssen Biotech, Inc. Humanized antibodies against paired helical filament tau and uses thereof

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI884505A (fi) 1987-10-02 1989-04-03 Du Pont Immunoanalys, i vilken anvaends igg-uppsnappande antikroppar och detekteringssystem foer flera monoklonala antikroppar.
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
US5733734A (en) 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
JP3909084B2 (ja) 1991-10-25 2007-04-25 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 微小管結合タンパク質タウに対するモノクローナル抗体
ATE438716T1 (de) 1991-12-06 2009-08-15 Max Planck Gesellschaft Verwendung von protein-kinasen zur diagnose und behandlung der alzheimer-krankheit
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
AU710952B2 (en) 1994-07-29 1999-09-30 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1998022120A1 (fr) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Reactifs pour traiter et diagnostiquer la maladie d'alzheimer
US6797478B1 (en) 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
RU2238947C2 (ru) * 1998-07-14 2004-10-27 Янссен Фармацевтика Н.В. Нейротрофический фактор роста человека (эновин), кодирующая его выделенная молекула нуклеиновой кислоты, вектор (варианты), фармацевтическая композиция (варианты), антитело, способ обнаружения фактора роста, набор, способ идентификации агониста или антагониста (варианты)
CA2340433A1 (fr) 1998-09-08 2000-03-16 Innogenetics N.V. Tau utilise comme marqueur dans le diagnostic precoce de lesions du systeme nerveux central
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
US20020182660A1 (en) 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
WO2003057881A1 (fr) 2001-12-28 2003-07-17 Chugai Seiyaku Kabushiki Kaisha Procede de stabilisation d'une proteine
HUE030806T2 (hu) 2002-05-02 2017-05-29 Wyeth Holdings Llc Calicheamicin származék-hordozó konjugátumok
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
DK1521831T3 (da) 2002-07-12 2008-06-30 Axon Neuroscience Transgent dyr der udtrykker trunkeret alzheimers tauprotein
EP1535930B1 (fr) 2002-08-14 2010-10-06 Mitsubishi Chemical Medience Corporation Anticorps specifique de la proteine tau du système nerveux central
FI20030652A0 (fi) 2003-04-30 2003-04-30 Susann Eriksson Parannettu immunomääritys
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
WO2005080986A1 (fr) 2004-02-18 2005-09-01 University Of Iowa Research Foundation Anticorps contre tau phosphorylee, procedes de fabrication et d'utilisation
WO2006088281A1 (fr) 2005-02-19 2006-08-24 Peoplebio, Inc. Procede de detection differentielle d'une forme multimere a partir d'une forme monomere de polypeptides formant des multimeres
US20070134724A1 (en) 2005-08-04 2007-06-14 Peter Davies Phosphorylation of tau by abl
ES2321996B1 (es) 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
CN102076339A (zh) 2008-04-24 2011-05-25 百时美施贵宝公司 埃坡霉素D在治疗包括阿尔茨海默病的τ相关疾病中的用途
CN101307108B (zh) 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
DK2365802T3 (da) * 2008-11-11 2017-11-13 Univ Texas Mikrokapsler af rapamycin og anvendelse til behandling af cancer
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
WO2010096751A1 (fr) 2009-02-23 2010-08-26 The Board Of Trustees Of The University Of Illinois Compositions et méthodes de traitement d'une maladie médiée par le bêta-amyloïde oligomère soluble
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8409584B2 (en) 2009-05-05 2013-04-02 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
CA3120504A1 (fr) * 2009-06-10 2010-12-16 New York University Ciblage immunologique de proteines tau pathologiques
SG177637A1 (en) * 2009-07-30 2012-03-29 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
JP6124591B2 (ja) 2009-08-28 2017-05-10 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム タウオリゴマーに結合する抗体
US20130022982A1 (en) * 2009-09-14 2013-01-24 Kevin Ka-Wang Wang Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
EP2480891B1 (fr) 2009-09-24 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Interaction fkbp52-tau en tant que nouvelle cible thérapeutique pour le traitement de troubles neurologiques impliquant un dysfonctionnement tau
US20130095492A1 (en) 2010-03-05 2013-04-18 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
AU2013205313B2 (en) 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
TW201216985A (en) * 2010-10-07 2012-05-01 Ac Immune Sa Pharmaceutical composition
JP2014503178A (ja) * 2010-10-11 2014-02-13 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗タウ抗体
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
US8697076B2 (en) 2011-04-27 2014-04-15 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
US20120321594A1 (en) 2011-05-06 2012-12-20 New York University Methods of controlling axon or dendrite development of neuronal cells
US9506051B2 (en) 2011-05-20 2016-11-29 Oligomerix, Inc. Tau protease compositions and methods of use
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US9926353B2 (en) 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
SG10201912964PA (en) 2011-09-19 2020-02-27 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
EP2764022B9 (fr) 2011-10-07 2017-02-22 AC Immune S.A. Anticorps phosphospécifiques reconnaissant tau
US20140294724A1 (en) 2011-10-24 2014-10-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
JP6306513B2 (ja) 2011-12-20 2018-04-04 ヤンセン バイオテツク，インコーポレーテツド 抗ＰＨＦ−ｔａｕ抗体及びその使用
MX356800B (es) 2012-04-05 2018-06-13 Ac Immune Sa Anticuerpo tau humanizado.
WO2013177104A2 (fr) 2012-05-21 2013-11-28 Felder Mitchell S Traitement de tauopathies
DK2857039T3 (da) 2012-05-31 2019-12-16 Univ Osaka City Terapeutisk middel eller profylaktisk middel mod demens
CN104781278B (zh) 2012-07-03 2018-06-12 华盛顿大学 针对tau的抗体
MX359817B (es) 2012-08-16 2018-10-11 Ipierian Inc Anticuerpos que se enlazan a tau.
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
JP2015527369A (ja) 2012-08-21 2015-09-17 インスティテュート フォー モレキュラー メディシン， インコーポレイテッド アミロイド、タウおよびα−シヌクレインの沈着に関連する疾患に関する組成物および方法
EP2906596B1 (fr) 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Réactifs à base d'anticorps qui reconnaissent spécifiquement des formes oligomériques toxiques de tau
WO2014089104A1 (fr) 2012-12-03 2014-06-12 Washington University Procédé de détection d'agrégats dans des échantillons biologiques
US8921150B2 (en) 2012-12-06 2014-12-30 Taiwan Semiconductor Manufacturing Co., Ltd. Process to achieve contact protrusion for single damascene via
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
WO2014096321A1 (fr) 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps spécifiques de la protéine tau phosphorylée à la sérine 422 et leurs utilisations pour traiter et diagnostiquer les tauopathies
EA035932B1 (ru) 2012-12-21 2020-09-02 Байоджен Ма Инк. Человеческие анти-тау антитела
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
AU2014248515B2 (en) 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
WO2014159244A2 (fr) 2013-03-14 2014-10-02 Merck Patent Gmbh Anticorps tau d'o-glcnac et son utilisation
MX2015012872A (es) 2013-03-15 2016-02-03 Ac Immune Sa Anticuerpos anti-tau y metodos de uso.
CN105283196B (zh) 2013-03-15 2018-10-12 贝丝以色列女执事医疗中心 用于产生和使用构象-特异性抗体的方法和组合物
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體

Also Published As

Publication number Publication date
HK1209768A1 (en) 2016-04-08
CA2877397A1 (fr) 2014-01-09
MX2014016024A (es) 2015-04-13
JP2015530971A (ja) 2015-10-29
KR20200134339A (ko) 2020-12-01
MX2022000026A (es) 2022-03-22
IL289241A (en) 2022-02-01
US9834596B2 (en) 2017-12-05
AU2018229564A1 (en) 2018-10-04
EP3838921A2 (fr) 2021-06-23
IL236409B (en) 2020-10-29
SG10201913370PA (en) 2020-03-30
EP2870176A1 (fr) 2015-05-13
AU2013286680B2 (en) 2018-07-05
IL236409A0 (en) 2015-02-26
US20180037641A1 (en) 2018-02-08
SG10201708959WA (en) 2017-11-29
IL277643A (en) 2020-11-30
KR102494798B1 (ko) 2023-02-06
CN104781278A (zh) 2015-07-15
NZ739622A (en) 2020-01-31
AU2020223765A1 (en) 2020-09-17
EP3838921A3 (fr) 2021-09-01
WO2014008404A1 (fr) 2014-01-09
US20150183855A1 (en) 2015-07-02
JP2020125310A (ja) 2020-08-20
KR20200013072A (ko) 2020-02-05
JP2018184398A (ja) 2018-11-22
NZ703423A (en) 2018-02-23
AU2013286680A1 (en) 2015-01-22
RU2018132044A (ru) 2018-10-19
KR20150036346A (ko) 2015-04-07
BR112014033116A2 (pt) 2018-03-06
CN104781278B (zh) 2018-06-12
EP2870176A4 (fr) 2016-09-28
RU2015103228A (ru) 2016-08-20
RU2668159C2 (ru) 2018-09-26
SG11201408626YA (en) 2015-03-30
CN108623682A (zh) 2018-10-09
RU2015103228A3 (fr) 2018-03-05
MX359555B (es) 2018-10-02
MY171473A (en) 2019-10-15
JP6345655B2 (ja) 2018-06-20

Similar Documents

Publication Publication Date Title
MX2022000026A (es) Anticuerpos para tau.
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
HK1212256A1 (en) Anti-mcam antibodies and associated methods of use -mcam
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
IL245237A0 (en) New anti-claudin antibodies and methods of use
MX2014004022A (es) Anticuerpos anti-htra1 y metodos de uso.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MX2015013901A (es) Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos.
IN2015DN00127A (fr)
EP2970508A4 (fr) Anticorps à charge génétiquement modifiée ou compositions de protéines de ciblage à pénétration améliorée et méthodes d'utilisation
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
IL245946A0 (en) Anti-dpep3 antibodies and methods of use
IN2014DN08721A (fr)
MX354303B (es) Anticuerpos de anti-biotina y metodos de uso.
IN2013MU00848A (fr)
IN2014DN09450A (fr)
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
MX2014014443A (es) Agentes de ligacion a tlr3.
MX2015010789A (es) Anticuerpos anti-pcsm.
NZ743971A (en) Antibodies to tau